This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Remedy Informatics First And Only Vendor Authorized To Submit Full Suite Of AGNIS-Supported CIBMTR Forms, Launches "Live In Five" Software Deployment Program

SALT LAKE CITY, Feb. 13, 2013 /PRNewswire/ -- Remedy Informatics today announced that it is the first vendor authorized by the Center for International Blood & Marrow Transplant Research (CIBMTR) to submit all CIBMTR forms currently supported by CIBMTR's AGNIS system. This achievement represents a significant milestone in Remedy's efforts to help its clients improve clinical outcomes for BMT patients by giving BMT centers the tools necessary to easily access and analyze clinical data.


Remedy officially launched its "Live In Five" program, committing to deploy a fully functional instance of ComprehensiveBMT throughout a BMT center in only five business days.

"The purpose of Remedy Informatics' clinical products is to support our clients' efforts to improve patient care by providing software solutions that will accelerate both clinical research and quality improvement initiatives — that is the central focus of ComprehensiveBMT," said Jonathan Dewey, MD, director of clinical products at Remedy Informatics. "Furthermore, our new five-day deployment strategy has already enabled our clients to derive benefits almost immediately. This is unlike traditional institution-wide software installations and deployments that can take months or years, and are often mired in red tape along the way."

Dr. Douglas Rizzo, CIBMTR's Associate Scientific Director for Data Operations and CIBMTR Executive Committee member, corroborated Remedy's claim. "Remedy Informatics has demonstrated the ability to submit data for all CIBMTR forms currently supported by the AGNIS system, and is now authorized by the CIBMTR for this activity in AGNIS," said Rizzo. "Expanded forms submission by Remedy represents one of several examples of increasing utilization of the AGNIS application to automate data exchange with the CIBMTR for the benefit of transplant centers and researchers."

In addition, Remedy Informatics offers a version of its Investigate™ product, specially designed for Cell Therapy labs. InvestigateCT™ is an integrated research management system designed to provide BMT and cell therapy laboratories an end-to-end service line production and research system. InvestigateCT operationalizes cell products biobanking, cell processing laboratory protocols and research study management, all on the same Mosaic™ Platform as ComprehensiveBMT. Which means that both products are automatically able to share data, annotations, results and gain a composite view of each patient, subject or donor.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.74 0.00%
FB $117.58 0.00%
GOOG $693.01 0.00%
TSLA $240.76 0.00%
YHOO $36.60 0.00%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs